Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods) (Lidocaine 04)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00651313
Recruitment Status : Completed
First Posted : April 2, 2008
Results First Posted : July 6, 2011
Last Update Posted : February 17, 2012
Information provided by (Responsible Party):
Juniper Pharmaceuticals, Inc.

Brief Summary:
The purpose of this study is to determine whether lidocaine vaginal gel is safe and effective for preventing or reducing the severity of dysmenorrhea (painful menstrual periods) compared to placebo (inactive gel).

Condition or disease Intervention/treatment Phase
Dysmenorrhea Drug: Lidocaine Drug: Placebo Phase 2

Detailed Description:

The primary objective of this study is to evaluate the efficacy of 10% (150 mg) lidocaine gel compared with placebo in reducing the severity and onset of primary dysmenorrhea in women with recurrent dysmenorrhea.

The secondary objectives of this study are the following:

  • to assess the safety of 10% (150 mg) lidocaine gel compared with placebo
  • to evaluate electrocardiograms (ECGs) for potentially significant QT changes at approximate peak lidocaine plasma concentration after 4 days of dosing with 10% (150 mg) lidocaine gel.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase II, Double-Blind, Crossover Study to Assess the Efficacy and Safety of 10% (150mg) Lidocaine Vaginal Gel Administered to Women With Recurrent Dysmenorrhea
Study Start Date : August 2007
Actual Primary Completion Date : June 2008
Actual Study Completion Date : August 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Period Pain

Arm Intervention/treatment
Active Comparator: Active
Lidocaine 10% (150mg) vaginal gel
Drug: Lidocaine
Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days

Placebo Comparator: Placebo
Placebo vaginal gel
Drug: Placebo
Placebo vaginal gel administered once daily for 4 days

Primary Outcome Measures :
  1. The Primary Efficacy Variable Will be the Time-weighted Average Pain Intensity Over 4 Treatment Days Using the 4 Point Categorical Scale. [ Time Frame: Two 4-day dosing regimens for two consecutive monthy menstrual cycles ]
  2. Treatment-emgergent Adverse Events [ Time Frame: approximately two months, based on onset of menses ]

Secondary Outcome Measures :
  1. Evaluate Electrocardiograms (ECGs) for Potentially Significant QT Changes at Approximate Peak Lidocaine Plasma Concentration After 4 Days of Dosing [ Time Frame: 7 hours following fourth dose in 2 consecutive menstrual cycles ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Experiences primary dysmenorrhea requiring pain medication for moderate-to-severe pain (as measured by a 4-point categorical rating scale) by the subject's own report for at least four of the previous six menstrual cycles.
  2. Has a history of primary dysmenorrhea with onset within 4 years of menarche.
  3. Has regular menstrual cycles (i.e. onset of menses predictable within 1 - 2 days each month) for the 3 month period preceding enrollment. If a subject has had regular cycles for the past 12 months but had a single cycle that was not regular within the 3 month period preceding enrollment, the subject may be enrolled at investigator discretion after consultation with sponsor.
  4. Taking the same strength and type of hormonal contraception on a monthly cycle for at least the previous 6 months prior to screening and plans to remain on this hormonal contraception for the duration of participation in the study or is on an acceptable method of birth control including surgical sterilization (i.e. bilateral tubal ligation, partner vasectomy), double-barrier methods, and total abstinence (at the discretion of the investigator in cases where age, career, lifestyle, or sexual orientation of the patient ensures compliance).
  5. Is a tampon user and/or must be willing to use tampons throughout the study dosing period.
  6. Age 18 to 40 years (inclusive).
  7. Has a Body Mass Index (BMI) ≤ 35 kg/m2.
  8. Able to understand and willing to complete the efficacy evaluations.
  9. Able to speak and understand English, and must give written informed consent for the study.

Exclusion Criteria:

  1. Unable, in the opinion of the Investigator, to comply fully with any of the study requirements.
  2. Experiencing pelvic pain other than that thought to be associated with primary dysmenorrhea, such as chronic pelvic pain occurring at times other than exclusively during menses and/or dyspareunia.
  3. Experiencing dysmenorrhea symptoms that are effects of or thought to be effects of (at least in part) secondary causes of dysmenorrhea, such as uterine fibroids, endometriosis, and/or currently symptomatic ovarian cysts.
  4. Experienced dysmenorrhea that did not require, in the opinion of the subject, the use of analgesic medication during four of the previous six menstrual episodes.
  5. Has dysmenorrhea refractory to treatment with commonly used analgesic medications for the treatment of menstrual pain (e.g., ibuprofen or naproxen sodium).
  6. Use of any Class I antiarrhythmic drug.
  7. Currently using contraceptive injection, implant, or extended cycle OC (hormonal contraceptive cycles consisting of 28 days or more of active hormones).
  8. Pregnant or breastfeeding.
  9. Participated in a clinical trial in the 30 days from the time of last dosing in the prior study to the time of providing consent for this study.
  10. Previously randomized into this study.
  11. A history of allergic hypersensitivity or significant intolerance (including angioedema, urticaria, bronchospasm, and rhinitis) related to treatment with any medications used in this study.
  12. A history of past or ongoing clinically significant disease, illness, or disorder that, in the opinion of the Investigator, makes the subject unsuitable for study participation including active vaginal, vulvar, and cervical lesions.
  13. Laboratory abnormalities that, in the opinion of the Investigator, could contraindicate study participation such as liver function tests > 1.5 times the upper limit of normal (At the Investigator's discretion, laboratory tests may be repeated once for verification.)
  14. A history of, within the past 4 years, or ongoing significant psychiatric illness that, in the opinion of the Investigator, makes the subject unsuitable for study participation.
  15. A history of chronic analgesic or tranquilizer use or drug abuse including alcohol within the 6 months before providing consent for this study.
  16. Regular use of any concomitant medications that might confound efficacy and/or safety assessments, in the opinion of the Investigator, including, but not limited to, the following: psychotropic drugs, antidepressants, sedative-hypnotics, sedating antihistamines, or tranquilizers for 24 hours or five half-lives prior to providing informed consent until 24 hours after the final treatment cycle. Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and St. John's Wort are permitted for indications other than pain if the subject has been on a stable dose for at least 2 weeks before providing consent for this study and agrees to remain on a stable dose throughout the course of the study.
  17. Unwilling to use only those medications that are allowed in the study for the treatment of their dysmenorrhea, i.e., study drug and rescue medication.
  18. Any ongoing vaginal infection requiring intravaginal treatment.
  19. A history of toxic shock syndrome (TSS).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00651313

United States, North Carolina
Lyndhurst Gynecologic Associates
Winston-Salem, North Carolina, United States, 27103
United States, Tennessee
SCIREX Research Center
Memphis, Tennessee, United States, 38120
United States, Texas
SCIREX Research Center
Austin, Texas, United States, 78705
United States, Utah
Jean Brown Research
Salt Lake City, Utah, United States, 84124
Sponsors and Collaborators
Juniper Pharmaceuticals, Inc.
Study Director: George W Creasy, MD Juniper Pharmaceuticals, Inc.

Responsible Party: Juniper Pharmaceuticals, Inc. Identifier: NCT00651313     History of Changes
Other Study ID Numbers: COL-1077-04
First Posted: April 2, 2008    Key Record Dates
Results First Posted: July 6, 2011
Last Update Posted: February 17, 2012
Last Verified: February 2012

Keywords provided by Juniper Pharmaceuticals, Inc.:
Primary dysmenorrhea in women with recurrent dysmenorrhea

Additional relevant MeSH terms:
Menstruation Disturbances
Pathologic Processes
Pelvic Pain
Neurologic Manifestations
Signs and Symptoms
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action